Eric Devroe
2022
In 2022, Eric Devroe earned a total compensation of $2.2M as Chief Operating Officer at Acrivon Therapeutics, a 371% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $228,000 |
|---|---|
| Option Awards | $1,147,830 |
| Salary | $386,779 |
| Stock Awards | $417,288 |
| Total | $2,179,897 |
Devroe received $1.1M in option awards, accounting for 53% of the total pay in 2022.
Devroe also received $228K in non-equity incentive plan, $386.8K in salary and $417.3K in stock awards.
Rankings
In 2022, Eric Devroe's compensation ranked 1,645th out of 5,760 executives tracked by ExecPay. In other words, Devroe earned more than 71.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,645 out of 5,760 | 71st |
Division Manufacturing | 849 out of 3,136 | 73rd |
Major group Chemicals And Allied Products | 336 out of 1,422 | 76th |
Industry group Drugs | 310 out of 1,323 | 77th |
Industry Pharmaceutical Preparations | 223 out of 969 | 77th |
Source: SEC filing on May 1, 2023.
Devroe's colleagues
We found two more compensation records of executives who worked with Eric Devroe at Acrivon Therapeutics in 2022.